Squarepoint
NRXP icon

Squarepoint’s NRX Pharmaceuticals NRXP Stock Holding History

Squarepoint’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.8K Buy
+13,166
New +$43.5K ﹤0.01% 4263
2025
Q3 		– Sell
-42,202
Closed -$138K – 4781
2025
Q2 		$138K Buy
+42,202
New +$106K ﹤0.01% 4082
2025
Q1 		– Sell
-25,299
Closed -$55.7K – 5152
2024
Q4 		$55.7K Buy
+25,299
New +$34K ﹤0.01% 4822
2022
Q1 		– Sell
-2,950
Closed -$141K – 3307
2021
Q4 		$141K Buy
+2,950
New +$213K ﹤0.01% 2833

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint's NRXP Position: Q2 2026 in Review

Squarepoint opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 13,166 shares worth $53.8K. The stake represents ﹤0.01% of the portfolio and ranks #4263 among its holdings. This is a return to the name: Squarepoint previously reported a position in NRXP as recently as Q2 2025.

Squarepoint first reported a position in NRXP in Q4 2021 and has held it in 4 quarters since. The position peaked at $141K in Q4 2021. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Squarepoint held 13,166 shares of NRX Pharmaceuticals worth $53.8K as of Q2 2026.
  • NRX Pharmaceuticals was a new Squarepoint position in Q2 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4263 holding.
  • Squarepoint first reported a position in NRX Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • Squarepoint's NRX Pharmaceuticals position peaked at $141K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.